FDA invites stakeholder input to shape a new Quantitative Medicine Innovation Network

The FDA announced it is looking for feedback from a broad range of stakeholders to help design a Quantitative Medicine Innovation Network (QMIN).

The proposed QMIN would be a cross-sector platform that applies quantitative methods to speed up drug development, enhance regulatory science, and support clinical decision-making.

The agency is seeking comments on the network’s structure, governance, and potential activities, and will use the input to shape the initiative.

By gathering diverse perspectives, the FDA aims to foster collaboration among industry, academia, and government to advance the use of quantitative approaches in the pharmaceutical pipeline.